Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, I…
FAIL · Does not pass the screen
21.14 USD
Price as of 28 Oct 2026Daily close, not a live quote
Screened 2026-10-28 · the tape above runs as of 18:02 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price21.14 USD at the 28 Oct 2026 close
Ethical screenDoes not pass
OptionsOpen interest leans heavily to calls (put/call 0.18)
Last reviewed28 Oct 2026 (1 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 21.14 against the desk's fair-value range, base estimate 24.12, over the last year.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.18, read 2026-10-28
Ethical does not pass the values gate
Price21.14 USD
Fair value24.12
Ethical score70.0/100
Our investment reviews on this name
2026-10-26Read Accumulation19.84+6.6% to today ✓Markup gives way to Accumulation after a 22% rise in 17 weeks
2026-07-02Read Markup16.20+30.5% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Amneal Pharmaceuticals, Inc. holds its Accumulation at $21.14. Elevated stress, defensive posture warranted, held for 48 days.
As held on the ledger · 2026-10-28
Phase
Accumulation
Quantitative state
Elevated stress, defensive posture warranted, held for 48 days
Price at the screen
$21.14
Valuation
40.49 trailing · 16.64 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.22
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
73.11%
Below 33%
Interest-bearing debt is 73.1% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
32.00%
Below 49%
Money owed to the company is 32.0% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Amneal Pharmaceuticals,'s business is in a permissible area, but its interest-bearing debt is about 73% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when AMRX's ethical verdict changes
Today AMRX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-28 screen. The gold marker is the market price at the same screen. A 14.1% margin of safety to the base estimate.
Third-party analyst targets: 7 covering, consensus Strong Buy. The average target sits +4% from the screen price.
Reading the gap · Our model sees value the Street hasn't fully caught up to yet.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-28 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Generic Drug Maker Stalls at Modest Valuation
Picture a pharmacy shelf stacked with copies of older medicines. Amneal makes and sells those generics plus a few injectables and specialty lines, yet revenue is expanding just 4% a year while net margins sit at 4%. The shares trade at 15.9 times forward earnings against our fair-value estimate, but the opportunity rating stays at none because growth and profitability give little headroom.
Analyst targets cluster at the current price and the competitive moat remains unknown, so the modest discount offers no real edge once thin returns and slow volume gains are factored in. Ethical screens clear, yet that alone does not turn a low-octane business into an attractive holding.
Risks centre on pricing pressure in generics, regulatory hurdles for new launches and limited cash generation that leaves little buffer if volumes slip further. Analysis, not advice.
The risks · The things to watch: as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
AMRX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-29Accumulation$21.14+6.6%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 6.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 36% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 96%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (5 analysts) rates it strong buy, with a mean price target of $17. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Accumulation$19.84+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 36% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 96%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (5 analysts) rates it strong buy, with a mean price target of $17. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Accumulation$19.84+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 36% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 96%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (5 analysts) rates it strong buy, with a mean price target of $17. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 36% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 96%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (5 analysts) rates it strong buy, with a mean price target of $17.
2026-10-19Markup$19.25-3.3%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 3.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 31% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 96%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (5 analysts) rates it strong buy, with a mean price target of $17.
2026-10-12Markup$19.91-1.2%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 1.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 96%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (5 analysts) rates it strong buy, with a mean price target of $17.
2026-10-02Markup$20.16+21.1%Entry 8
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 21.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 96%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (5 analysts) rates it strong buy, with a mean price target of $17. Since the last review it its composite score eased.
2026-09-21Markup$16.65-8.2%Entry 7
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 8.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 96%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (5 analysts) rates it strong buy, with a mean price target of $17.
2026-08-21Markup$18.14+1.6%Entry 6
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 96%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (5 analysts) rates it strong buy, with a mean price target of $17.
2026-07-21Markup$17.85+10.2%Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 96%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (5 analysts) rates it strong buy, with a mean price target of $17.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
